This site is intended for healthcare professionals

CHMP recommends a change to indication for Tecentriq in NSCLC.- Genentech/Roche

Read time: 1 mins
Published:23rd Apr 2022

The CHMP adopted a new indication for the treatment of early-stage non-small cell lung cancer (NSCLC). The additional indication for Tecentriq will be: Early-stage non-small cell lung cancer (NSCLC). Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on at least 50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.

Condition: Non Small Cell Lung Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights